Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies

Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies

Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics Methods: This retrospective cohort study analyzed pre-3V and post-3V...

Full description

Bibliographic Details
Main Authors: Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, James L. Weese
Format: Article
Language:English
Published: Advocate Aurora Health 2022-07-01
Series:Journal of Patient-Centered Research and Reviews
Subjects:
hematology
malignancy
covid-19
sars-cov-2
mrna vaccine
antibody
seroconversion
blood cancer
preventive care
Online Access:https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1952&context=jpcrr

Internet

https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1952&context=jpcrr

Similar Items